review discusses application alpha radionuclides targeted radioimmunotherapy outline production chemistry bismuth212 actinium225 fermium255 present promising isotopes available human clinical use selective cytotoxicity offered alpha radioimmunoconstructs high linear energy transfer short particle path length radionuclides based pharmacokinetics alpha radioimmunoconstructs stochastic conventional dosimetric methodology discussed preclinical initial clinical use radionuclides conjugated monoclonal antibodies treatment human neoplasia references NUMBER particle emitting astatine NUMBER lead NUMBER bismuth NUMBER radium NUMBER terbium NUMBER alpha emitting particle emitting particle emitting